Production (Stage)
Oragenics, Inc.
OGEN
$4.28
$0.7521.25%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -93.55% | -84.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -93.55% | -84.48% |
| Cost of Revenue | -73.81% | -73.44% | 130.20% | 70.07% | 71.35% |
| Gross Profit | 73.77% | 73.37% | -131.69% | -72.52% | -73.85% |
| SG&A Expenses | 5.55% | 18.20% | 41.95% | 40.62% | 36.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.56% | -49.58% | 91.47% | 59.40% | 59.40% |
| Operating Income | 50.51% | 49.49% | -92.16% | -60.86% | -60.91% |
| Income Before Tax | 49.00% | 48.84% | -96.79% | -62.59% | -61.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.00% | 48.84% | -96.79% | -62.59% | -61.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.00% | 48.84% | -96.79% | -62.59% | -61.55% |
| EBIT | 50.51% | 49.49% | -92.16% | -60.86% | -60.91% |
| EBITDA | 60.47% | 49.56% | -92.71% | -61.35% | -61.34% |
| EPS Basic | 83.85% | 78.51% | -36.10% | -18.07% | -27.52% |
| Normalized Basic EPS | 83.85% | 78.51% | -36.09% | -18.06% | -27.51% |
| EPS Diluted | 83.85% | 78.51% | -36.10% | -18.07% | -27.52% |
| Normalized Diluted EPS | 83.85% | 78.51% | -36.09% | -18.06% | -27.51% |
| Average Basic Shares Outstanding | 293.53% | 194.59% | 99.11% | 58.19% | 28.99% |
| Average Diluted Shares Outstanding | 293.53% | 194.59% | 99.11% | 58.19% | 28.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |